Project Grant K99AI175674

Award Date 6/6/24
Completion Date 5/31/25
Dollars Obligated $253K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $754,446 to the University of Tennessee Health Science Center to develop microbiome-sparing antibacterials for the treatment of Clostridioides difficile infection (CDI). The key objectives are to optimize and expand the structure-activity relationship (SAR) of lead CDFabK inhibitor compounds, identify novel CDFabK...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel probiotic yeast-based immunotherapy to prevent the transmission of Clostridioides difficile (C. difficile) infections. The $511,553 award to the University of Maryland, Baltimore will fund research to screen for lead bi-specific antibody fragments against the C. difficile surface protein...
This $894,552 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at the University of Nevada, Las Vegas to probe the effect of a high-fat/high-protein diet on Clostridioides difficile infection. Specifically, the researchers will examine how such a diet impacts inflammation, intestinal permeability, and the gut microbiome before and after antibiotic...
This Project Grant award of $1,005,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the molecular basis of ferrosome organelle biogenesis and its impact on host-microbe interactions in Clostridioides difficile, a leading cause of nosocomial and antibiotic-associated intestinal infections. The research aims to uncover the mechanisms underlying ferrosome formation and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $180,310 to the University of Oklahoma Health Sciences Center to conduct research on the interactions between Clostridioides difficile toxin B (TcdB) and the host cell surface proteoglycan CSPG4. The overarching goal is to understand how CSPG4 is used by the hypervirulent TcdB2 isotype to promote the pathologies...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $222,852 to support research into the regulation of virulence factors in the pathogenic bacterium Clostridioides difficile. The primary objective is to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in C. difficile to understand how these regulatory factors influence the...
This $261,492 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the impact of DNA methylation on the physiology of Clostridioides difficile, a major nosocomial pathogen. The research aims to identify specific methylation sites that regulate C. difficile sporulation, which enhances the bacterium's ability to persist. This effort builds on prior work...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $171,254 to the Nimml Institute Inc., a 501(c)(3) non-profit research organization, to elucidate novel immunometabolic mechanisms that can intercept bacterial toxin internalization and processing in order to suppress cell damage caused by Clostridioides difficile infection (CDI). The research aims to investigate...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research at the University of North Carolina at Chapel Hill to define the interplay between stochastic and regulatory mechanisms underlying the heterogeneous expression of flagella and toxins in Clostridioides difficile. The $521,030 award, effective from November 18, 2024 to October 31, 2029, will support...
This $780,162 Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at Old Dominion University from August 2022 through July 2026 exploring the role of nutrient and stress sensing in regulating Clostridioides difficile physiology and behavior within the host. The research aims to determine how the stringent response regulates disease-relevant bacterial processes and characterize enzymes that mediate alarmone metabolism...

IDENTIFYING SOURCES OF VARIATION IN MICROBIOME-PATHOGEN DYNAMICS DURING CLOSTRIDIOIDES DIFFICILE COLONIZATION - PROJECT SUMMARY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) IS A MAJOR CAUSE OF HEALTHCARE-RELATED MORTALITY AND A SIGNIFICANT PUBLIC HEALTH BURDEN IN THE US. C. DIFFICILE (CD) REMAINS A PERSISTENT CAUSE OF MORBIDITY AND MORTALITY IN HEALTHCARE SETTINGS, IN PART BECAUSE MANY PATIENTS ARE ASYMPTOMATIC FOR CDI YET COLONIZED WITH CD. THESE PATIENTS OUTNUMBER CDI PATIENTS, CAN TRANSMIT CD AND PROGRESS TO CDI (ESPECIALLY IN THE CONTEXT OF ANTIBIOTIC EXPOSURE). IMPORTANTLY, THE CLINICAL OUTCOMES IN CD-COLONIZED PATIENTS EXISTS ON A SPECTRUM INFLUENCED BOTH BY THE MICROBIAL COMMUNITY AND THE VIRULENCE OF THE CD STRAIN. CRITICALLY, CONVENTIONAL ANIMAL MODELS OF CDI DO NOT RECAPITULATE MICROBIOME AND PATHOGEN VARIATION SEEN IN ASYMPTOMATICALLY-COLONIZED PATIENTS, THUS REQUIRING THE DEVELOPMENT OF NOVEL ANIMAL MODELS TO STUDY THIS PATIENT POPULATION. THE LONG-TERM GOAL OF THIS RESEARCH IS TO IDENTIFY OPPORTUNITIES FOR NOVEL THERAPEUTIC INTERVENTION OR PATHOGEN SURVEILLANCE BY BETTER UNDERSTANDING AND PREDICTING CD-ASSOCIATED CLINICAL OUTCOMES. THE OBJECTIVE OF THIS PROPOSAL IS TO USE CLINICALLY-RELEVANT ANIMAL MODELS TO 1) INVESTIGATE THE EXTENT TO WHICH COMMENSAL MICROBIOTA PROTECT THE HOST FROM DIVERSE CD STRAINS, 2) PREDICT MICROBIOME VULNERABILITIES TO ANTIBIOTIC-INDUCED CDI, AND 3) IDENTIFY MICROBIOME FEATURES THAT SYNERGIZE WITH PREBIOTIC ADMINISTRATION. THE CENTRAL HYPOTHESIS OF THIS WORK IS THAT THE COMPOSITION OF THE COMMENSAL MICROBIOTA PLAYS A CENTRAL ROLE IN DETERMINING HOST DISEASE SEVERITY. THE SPECIFIC AIMS OF THIS PROPOSAL ARE TO: 1) INVESTIGATE THE IN VIVO ROLE OF COMMENSAL EUBACTERIACEAE IN MICROBIOME-BASED PROTECTION AGAINST CD INFECTION AND 2) IDENTIFY MICROBIOME CORRELATES OF ANTIBIOTIC-INDUCED CDI AND PREBIOTIC SYNERGY. THE PROPOSAL WILL USE MICROBIOME-HUMANIZED MODELS OF CD COLONIZATION/INFECTION THAT INTEGRATE BOTH CLINICALLY-REPRESENTED CD STRAINS AND PATIENT-DERIVED BACTERIAL COMMUNITIES TO UNDERSTAND THE MICROBIOTA'S IMPACT ON HOST INFLAMMATION, COMMUNITY METABOLISM, AND CD PROLIFERATION. THIS RESEARCH WILL SPUR THE DEVELOPMENT OF INNOVATIVE TREATMENT AND DIAGNOSTIC APPROACHES TO MITIGATING CDI. DR. DANTAS WILL OVERSEE THE PROJECT, PROVIDE DIRECT MENTORING ON STATISTICAL MODELING OF MULTI-OMICS DATA, AND HELP DR. FISHBEIN'S TRANSITION TO INDEPENDENCE THROUGH SUPPORT OF NETWORKING STRATEGIES. DR. FISHBEIN HAS PREPARED A SCHOLARLY ADVISORY COMMITTEE ALONG WITH OTHER SIGNIFICANT CONTRIBUTORS WITH EXPERTISE IN HOST-PATHOGEN INTERACTIONS, GUT MICROBIOME-PATHOGEN DYNAMICS, AND INTESTINAL INFLAMMATION. THE TRAINING PLAN COMBINES PRIMARY MENTORSHIP, COMMITTEE INTERACTIONS, FORMAL COURSEWORK (AT THE UNIVERSITY AND EXTERNALLY), AND SEMINAR/CONFERENCE PRESENTATIONS TO EXPAND DR. FISHBEIN'S TECHNICAL AND CONCEPTUAL FOUNDATIONS IN THE MICROBIOME FIELD. THIS AWARD WILL FACILITATE DR. FISHBEIN'S ACQUISITION OF INDEPENDENT FUNDING, ENABLING HER TRANSITION TO AN INDEPENDENT RESEARCH PROGRAM AT A RESEARCH-INTENSIVE ACADEMIC INSTITUTION.

Posted 6/6/24, 12:00 AM